Northland Securities Weighs in on CNTB Q1 Earnings

Key Points

• Northland Securities forecasts Connect Biopharma will report Q1 2026 EPS of ($0.35) and FY2026 EPS of ($0.75), with a FY2027 loss estimate of ($1.80) (it also models a small Q4 2026 profit of $0.07).
• Analyst sentiment is mixed but leans positive: the stock has a consensus Moderate Buy rating with a $8.67 target (breakdown: 1 Strong Buy, 3 Buy, 1 Sell), while individual firms range from Weiss's "sell (d-)" to BTIG's "buy" with a $10 target.
• A significant insider purchase occurred—Director James Huang bought 1,160,000 shares at $3.45 (~$4.00M), increasing his holdings to 13,160,000 shares and contributing to insiders owning 22.60% of the company.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities research analysts at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Connect Biopharma in a report issued on Thursday, April 23rd. Northland Securities analyst C. Byrnes forecasts that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.91) per share. Northland Securities also issued estimates for Connect Biopharma's Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($1.80) EPS.

Several other research firms also recently commented on CNTB. Weiss Ratings reissued a "sell (d-)" rating on shares of Connect Biopharma in a research note on Wednesday, January 21st. BTIG Research reissued a "buy" rating and issued a $10.00 price objective on shares of Connect Biopharma in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.67.

Connect Biopharma Price Performance

NASDAQ CNTB opened at $2.52 on Monday. The business has a fifty day moving average price of $2.78 and a 200 day moving average price of $2.46. Connect Biopharma has a one year low of $0.70 and a one year high of $3.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 3.74. The company has a market cap of $142.43 million, a P/E ratio of -2.52 and a beta of -0.21.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The business had revenue of ($0.05) million during the quarter, compared to analysts' expectations of $0.00 million.

Institutional Trading of Connect Biopharma

Large investors have recently added to or reduced their stakes in the stock. SmartHarvest Portfolios LLC purchased a new stake in Connect Biopharma in the 4th quarter valued at $36,000. HRT Financial LP grew its holdings in Connect Biopharma by 60.5% in the 4th quarter. HRT Financial LP now owns 16,785 shares of the company's stock valued at $47,000 after buying an additional 6,328 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Connect Biopharma in the 4th quarter valued at $76,000. XTX Topco Ltd purchased a new stake in Connect Biopharma in the 2nd quarter valued at $29,000. Finally, Royal Bank of Canada purchased a new stake in Connect Biopharma in the 4th quarter valued at $114,000. 58.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director James Huang acquired 1,160,000 shares of Connect Biopharma stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average cost of $3.45 per share, with a total value of $4,002,000.00. Following the purchase, the director owned 13,160,000 shares in the company, valued at $45,402,000. This trade represents a 9.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.60% of the company's stock.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company's lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.